Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan · Delayed Price · Currency is TWD 354.50
-6.50 (-1.80%)
Feb 2, 2026, 1:35 PM CST
Lotus Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 18,656 | 18,584 | 16,958 | 14,633 | 12,649 | 10,729 | |
Revenue Growth (YoY) | 6.04% | 9.59% | 15.89% | 15.68% | 17.90% | 11.63% |
Cost of Revenue | 7,787 | 7,660 | 7,574 | 6,827 | 7,009 | 6,132 |
Gross Profit | 10,869 | 10,924 | 9,384 | 7,806 | 5,640 | 4,597 |
Selling, General & Admin | 4,401 | 4,133 | 3,764 | 3,141 | 2,703 | 2,473 |
Research & Development | 880.69 | 613.9 | 541.46 | 419.01 | 373.84 | 384.14 |
Operating Expenses | 5,279 | 4,744 | 4,302 | 3,557 | 3,112 | 2,856 |
Operating Income | 5,590 | 6,180 | 5,082 | 4,249 | 2,529 | 1,740 |
Interest Expense | -525.37 | -561.39 | -533.69 | -356.22 | -266.69 | -304.45 |
Interest & Investment Income | 112.88 | 101.44 | 31.55 | 3.51 | 5.34 | 3.76 |
Earnings From Equity Investments | - | - | - | - | - | 3.78 |
Currency Exchange Gain (Loss) | -19.47 | 168.11 | 91.67 | -81.22 | -119.23 | 40.45 |
Other Non Operating Income (Expenses) | 71.55 | 28.84 | 23.94 | -10.31 | 1.78 | -9.4 |
EBT Excluding Unusual Items | 5,230 | 5,917 | 4,696 | 3,805 | 2,150 | 1,474 |
Gain (Loss) on Sale of Investments | 836.25 | 604.16 | 715.05 | 286.81 | - | - |
Gain (Loss) on Sale of Assets | -9.67 | -0.64 | -24.75 | 2.52 | -3.2 | -4.68 |
Asset Writedown | -159.99 | -159.99 | -179.37 | -138.26 | -233.18 | -127.68 |
Other Unusual Items | - | -0.91 | -103.79 | -16 | -43.42 | -40.31 |
Pretax Income | 5,896 | 6,360 | 5,103 | 3,940 | 1,870 | 1,302 |
Income Tax Expense | 1,165 | 1,294 | 997.3 | 919.46 | 466.65 | 274.58 |
Earnings From Continuing Operations | 4,731 | 5,066 | 4,106 | 3,021 | 1,403 | 1,027 |
Minority Interest in Earnings | - | - | - | - | - | -0.42 |
Net Income | 4,731 | 5,066 | 4,106 | 3,021 | 1,403 | 1,027 |
Net Income to Common | 4,731 | 5,066 | 4,106 | 3,021 | 1,403 | 1,027 |
Net Income Growth | 9.19% | 23.38% | 35.91% | 115.25% | 36.68% | 54.92% |
Shares Outstanding (Basic) | 261 | 262 | 261 | 261 | 255 | 243 |
Shares Outstanding (Diluted) | 262 | 263 | 262 | 262 | 257 | 243 |
Shares Change (YoY) | -0.26% | 0.53% | 0.13% | 1.95% | 5.43% | 0.65% |
EPS (Basic) | 18.13 | 19.35 | 15.72 | 11.59 | 5.50 | 4.22 |
EPS (Diluted) | 18.04 | 19.23 | 15.67 | 11.54 | 5.47 | 4.22 |
EPS Growth | 9.46% | 22.72% | 35.79% | 110.97% | 29.62% | 54.02% |
Free Cash Flow | 7,334 | 5,801 | 1,204 | 3,142 | -453.07 | 1,535 |
Free Cash Flow Per Share | 27.97 | 22.02 | 4.59 | 12.01 | -1.76 | 6.30 |
Dividend Per Share | 5.779 | 5.779 | 4.660 | 3.460 | 1.930 | 0.350 |
Dividend Growth | 24.00% | 24.00% | 34.68% | 79.27% | 451.43% | - |
Gross Margin | 58.26% | 58.78% | 55.34% | 53.35% | 44.59% | 42.84% |
Operating Margin | 29.96% | 33.25% | 29.97% | 29.04% | 19.99% | 16.22% |
Profit Margin | 25.36% | 27.26% | 24.21% | 20.64% | 11.09% | 9.57% |
Free Cash Flow Margin | 39.31% | 31.21% | 7.10% | 21.47% | -3.58% | 14.31% |
EBITDA | 6,876 | 7,331 | 6,171 | 5,094 | 3,204 | 2,365 |
EBITDA Margin | 36.85% | 39.45% | 36.39% | 34.81% | 25.33% | 22.04% |
D&A For EBITDA | 1,286 | 1,151 | 1,088 | 844.44 | 675.77 | 624.19 |
EBIT | 5,590 | 6,180 | 5,082 | 4,249 | 2,529 | 1,740 |
EBIT Margin | 29.96% | 33.25% | 29.97% | 29.04% | 19.99% | 16.22% |
Effective Tax Rate | 19.76% | 20.35% | 19.54% | 23.34% | 24.95% | 21.09% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.